Portal de Periódicos da CAPES

Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experience.

2006; American Medical Association; Volume: 130; Issue: 8 Linguagem: Inglês

10.1043/1543-2165(2006)130[1157

1543-2165

George J. Netto, David L. Watkins, James W. Williams, Thomas V. Colby, Giovanni De Petris, Francis E. Sharkey, Christopher L. Corless, David Lewin, Lydia Petrovic, Shobha Sharma, Gary C. Kanel, Neil D. Theise, A. Brian West, Alison Koehler, Nirag Jhala, Jay H. Lefkowitch, Julia Lezzoni, Linda W. Jennings, G. Weldon Tillery, Göran B. Klintmalm,

Hepatitis B Virus Studies

Abstract Context.—Establishing adequate interobserver agreement is crucial not only for standardization of patient care but also to ensure validity of findings in multi-institutional trials. Objective.—To evaluate interobserver agreement in assessing chronic hepatitis C (HCV) and acute cellular rejection (ACR) among 17 hepatopathologists involved in the “Hepatitis C 3” trial. Design.—The trial is a randomized multicenter (17 institutions) study involving 312 patients undergoing transplantation for HCV. Patients are randomized to 3 treatment arms. For final data analysis, all biopsy specimens are reviewed by a central pathologist (G.J.N.). Recurrence of HCV is evaluated according to the Batts and Ludwig schema. The 1997 Banff schema is used to evaluate ACR. To assess interobserver agreement, hematoxylin-eosin–stained sections from 11 liver biopsy specimens (6 HCV and 5 ACR) were sent by the central pathologist to 16 local pathologists from 13 institutions. Statistical analysis was performed on raw ACR/HCV ...